Jerini's first-half net loss inches up

Berlin, Germany-based Jerini AG has reported a slight improvement in sales and a small widening in its loss for the first half of 2007. Total revenues reached 6.9 million euros ($9.4 million), while its deficit was 12.1 million euros versus 11.0 million euros. R&D expenses remained nearly unchanged at 11.6 million euros, while cash and equivalents at end-June amounted to 53.7 million euros.

The highlight of the reporting period was the filing of a Marketing Authorization Application for icatibant, a treatment for hereditary angioedema, with the European Medicines Agency (EMEA). Additionally, the EMEA granted Jerini accelerated assessment, which shortens the regulatory review process for the product from 210 to 150 days. In preparation for icatibant's launch, the company is establishing commercial infrastructure and implementing pre-marketing programs.